To Study Clinicopathological and Immunohistochemical Expression of Estrogen Receptor, Progesterone Receptor and Her-2/Neu in Prostate Carcinoma

  • Manpreet Kaur Department of Pathology, SGRD, Amritsar
  • Menka Khanna Department of Pathology, SGRD, Amritsar
  • Harjot Kaur Department of Pathology, SGRD, Amritsar
  • Rajeev Gupta Department of Medicine, SGRD, Amritsar
DOI: https://doi.org/10.21276/apalm.3001
Keywords: Prostate carcinoma, ER, PR, HER-2/neu, Biomarkers

Abstract

Background: Prostate carcinoma is leading cause of cancer related deaths amongst men. This study evaluated expression of ER, PR, HER-2/neu in Prostatic carcinoma and its correlation with Gleason score and other clinical parameters. Methods: 50 histopathologically proven PCa cases were subjected to IHC for ER, PR, HER-2/neu. Result:  Most common age group involved was 61-80years. Retention of urine was most frequent complaint.  Most prominent Gleason score was (3+4) and group grade was 2. ER expression in tumor epithelial cells was 24% and in stromal cells was 36%. PR expression in stromal cells was 32%. HER-2/neu Cytoplasmic positivity was seen in 6% cases. It was seen that with increase in Gleason grade, ER, PR, HER-2/neu positivity was decreased. Conclusion: ER, PR, HER-2/neu can be used as biomarkers in PCa management.

References

Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene. 2014;596-605.

Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of prostate cancer: pathologic criteria and clinical significance. Mod Pathol.1997;10:612-19.

Leach DA, Powell SM, Bevan CL. Women in cancer thematic review: new roles for nuclear receptors in prostate cancer. Endocrine-Related Cancer. 2016;23(11):T85-108.

Grimm, Hartig SM, Edwards DP. Progesterone receptor signaling mechanisms. J MolBiol.2016;428:3831–49.

Siampanopoulou A,Galaktidou G, Dimasis N, Gotzamani-Psarrakou A. Profiling serum HER-2/neu in prostate cancer. Hippokratia. 2013;17(2):108–12.

Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E et al. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol. 2008; 19:269-75.

Naskar S, Kundu SK, Bhattacharya NK. A study to correlate histopathology, biochemical marker and immune–histochemical expression of sex steroid receptors in prostatic growth. Indian J PaediatrOncol.2014;35(1):40-3.

Naskar S, Kundu SK, Bhattacharya NK, Bhattacharya PK, Kundu AK. A study to correlate histopathology, biochemical marker and immune-histochemical expression of sex steroid receptors in prostatic growth. Indian J PaediatrOncol. 2014;35(1):40-3.

Chen N, Zhou Q.The evolving Gleason grading system. Chin J Cancer Res. 2016;28(1):58–64.

Darnel AD, Lafargue CJ, Vollmer RT, Corcos J,Bismar TA. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer BiolTher. 2009;8(2):125-30.

Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S et al. Frequent loss of estrogen receptor-beta ex¬pression in prostate cancer. Cancer Res. 2001; 61: 5331-5.

Bonkhoff H. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate. 2001;48(4):285–91.

Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich D et al. Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. British Journal of Cancer. 2004;90(2):443-8.

Sahar Aly Daoud, Mohamed Faisal, Rehab Mohamed Sharaf. HER-2/neu immunostaining overexpression in Prostatic adenocarcinomas in relation to tumor pathological behavior. Middle East Journal of Scientific Research. 2016;24(2):459-64.

Published
2021-09-30
Issue
Vol 8 No 9 (2021)
Section
Original Article

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).